Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that Gilead Sciences, Inc. has exercised the first of its options to exclusively license a novel oncology target discovered and validated through Cartography's proprietary ATLAS and SUMMIT platforms arising out of the parties' collaboration. The option exercise represents a key milestone in the.